Literature DB >> 2949897

Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

E Braakman, A van Tunen, A Meager, C J Lucas.   

Abstract

In order to determine the factors underlying the impaired natural cytotoxic (NC) activity in multiple sclerosis (MS) patients, we have analysed the interleukin 2 (IL-2)-interferon gamma-(IFN gamma)-NC activity regulatory circuit in 40 MS patients and 40 matched healthy controls. Exogenous recombinant IFN gamma (rIFN gamma) enhanced NC activity in peripheral blood lymphocytes (PBL) derived from MS patients and controls equally well. In contrast, PBL from MS patients showed a significantly lower increase of NC activity in response to IL-2 than healthy controls. This defect in responsiveness was independent of the dose of IL-2. Even at the highest dose of rIL-2 (1000 U/ml), MS patients showed a decreased response. PBL from MS patients required a 2 to 10 times higher dose of IL-2 to reach NC activity levels comparable to controls. In healthy individuals IL-2 can act upon both Fc gamma R+ and Fc gamma R- NC precursor cells. The decreased responsiveness to IL-2 is not confined to one subpopulation of IL-2-responsive precursor cells because depletion of Fc gamma R+ cells before culture in the presence of IL-2 revealed no significant differences in the contribution of Fc gamma R+ precursor cells to the IL-2 enhanced NC activity between MS patients and controls. Also the number of IL-2-responsive precursor cells appeared to be normal since the number of Fc gamma R+ cells in MS patients and controls was comparable. PBL from MS patients produced significantly lower amounts of IFN gamma upon stimulation with IL-2. Analysis of the different parameters of the regulatory circuit at the population level showed, both for patients and controls, a significant correlation between IFN gamma production and increase of NC activity induced by IL-2. Also the endogenous NC activity and IFN gamma production, both in patients and controls, were correlated. At the individual level, defects in NC activity could not be linked to another parameter of the regulatory circuit.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949897      PMCID: PMC1542540     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Mechanisms in multiple sclerosis.

Authors:  B Waksman
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

Review 2.  Virologic studies of multiple sclerosis and other chronic and relapsing neurological diseases.

Authors:  R T Johnson; R M Herndon
Journal:  Prog Med Virol       Date:  1974

3.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  Ricin-resistant human T-cell hybridomas producing interferon gamma.

Authors:  I J Crane; H Leung; S Parti; A Meager
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

5.  Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell.

Authors:  D Santoli; G Trinchieri; L Moretta; C M Zmijewski; H Koprowski
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

6.  Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases.

Authors:  G Vervliet; H Carton; A Billiau
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

7.  Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.

Authors:  J F Bukowski; B A Woda; R M Welsh
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

8.  IL-2- and IFN gamma-enhanced natural cytotoxic activity: analysis of the role of different lymphoid subsets and implications for activation routes.

Authors:  E Braakman; A van Tunen; A Meager; C J Lucas
Journal:  Cell Immunol       Date:  1986-05       Impact factor: 4.868

9.  Natural killer cell activity in multiple sclerosis and myasthenia gravis.

Authors:  H C Rauch; I N Montgomery; J Kaplan
Journal:  Immunol Invest       Date:  1985-10       Impact factor: 3.657

10.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

3.  Cellular aspects of myasthenia gravis.

Authors:  S Berrih-Aknin; S Cohen-Kaminsky; D Neumann; D Safar; B Eymard; C Gaud; P Levasseur; S Fuchs; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D Donati; P Annunziata; G C Guazzi; D Boraschi; A Tagliabue
Journal:  Ital J Neurol Sci       Date:  1990-02

5.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 6.  Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications.

Authors:  Batol Abbasi; Karim Shamsasenjan; Majid Ahmadi; Seyedeh Ameneh Beheshti; Mahshid Saleh
Journal:  Stem Cell Res Ther       Date:  2022-03-07       Impact factor: 6.832

7.  Autologous enhancement by interferon of natural killer activity of human peripheral blood lymphocytes.

Authors:  S B Cheknev; Y G Ashmanova; A D Pritsker; O L Latysheva; F I Yershov; A J Kulberg
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.